Strategic Shifts and Financial Challenges at Pfizer

This chapter explores recent developments at Pfizer, focusing on Starboard Value's $1 billion investment amid the company's financial struggles following the pandemic. It also examines safety concerns regarding the drug Oxbrida as Pfizer seeks to recover from its decline in revenue.